Cancer Biotech Lands $145M for First-in-Class Drug to Block Elusive Tumor Target

Retrieved on: 2024-03-01 18:00:43

Tags for this article:

Click the tags to see associated articles and topics

Cancer Biotech Lands $145M for First-in-Class Drug to Block Elusive Tumor Target. View article details on hiswai:

Excerpt

FogPharma's lead program is a peptide that blocks a difficult-to-drug pathway inside of cells. The new financing will go toward an ongoing Phase ...

Article found on: medcitynews.com